IN2014MN02126A - - Google Patents

Info

Publication number
IN2014MN02126A
IN2014MN02126A IN2126MUN2014A IN2014MN02126A IN 2014MN02126 A IN2014MN02126 A IN 2014MN02126A IN 2126MUN2014 A IN2126MUN2014 A IN 2126MUN2014A IN 2014MN02126 A IN2014MN02126 A IN 2014MN02126A
Authority
IN
India
Prior art keywords
compounds
calcium
crac
channel
formula
Prior art date
Application number
Other languages
English (en)
Inventor
Nageswara Rao Irlapati
Zubair Abdul Wajid Shaikh
Vijay Pandurang Karche
Gokul Keruji Deshmukh
Neelima Sinha
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Priority to IN2126MUN2014 priority Critical patent/IN2014MN02126A/en
Publication of IN2014MN02126A publication Critical patent/IN2014MN02126A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN2126MUN2014 2012-05-02 2013-05-01 IN2014MN02126A (2)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN2126MUN2014 IN2014MN02126A (2) 2012-05-02 2013-05-01

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN6KO2012 2012-05-02
IN2126MUN2014 IN2014MN02126A (2) 2012-05-02 2013-05-01
PCT/IB2013/053440 WO2013164769A1 (en) 2012-05-02 2013-05-01 Substituted pyridine compounds as crac modulators

Publications (1)

Publication Number Publication Date
IN2014MN02126A true IN2014MN02126A (2) 2015-09-11

Family

ID=48428565

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2126MUN2014 IN2014MN02126A (2) 2012-05-02 2013-05-01

Country Status (7)

Country Link
US (2) US9399638B2 (2)
EP (1) EP2844655A1 (2)
AU (1) AU2013255437A1 (2)
CA (1) CA2871270A1 (2)
IN (1) IN2014MN02126A (2)
WO (1) WO2013164769A1 (2)
ZA (1) ZA201407685B (2)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10703722B2 (en) 2010-04-27 2020-07-07 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2014203217A1 (en) 2013-06-21 2014-12-24 Lupin Limited Substituted heterocyclic compounds as crac modulators
WO2014207648A1 (en) 2013-06-24 2014-12-31 Lupin Limited Chromane and chromene derivatives and their use as crac modulators
WO2015090579A1 (en) * 2013-12-18 2015-06-25 Grünenthal GmbH Pyrazolyl-based carboxamides iv
CN105367547B (zh) * 2014-08-19 2019-04-23 北京桦冠生物技术有限公司 一种噁唑啉酮抗生素的新合成工艺
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CA2968299A1 (en) 2014-11-18 2016-05-26 Rutgers, The State University Of New Jersey Novel mitochondrial uncouplers for treatment of metabolic diseases and cancer
EP3778595B1 (en) * 2015-02-27 2021-08-25 Calcimedica, Inc. Pancreatitis treatment
US20180161388A1 (en) 2015-05-18 2018-06-14 Beth Israel Deaconess Medical Center, Inc. Substance p, mast cell degranulation inhibitors, and peripheral neuropathy
PL3303330T3 (pl) * 2015-06-03 2019-10-31 Bristol Myers Squibb Co Agoniści 4 - hydroksy - 3 - ( heteroarylo ) pirydyno - 2 - onowi receptora apj do stosowania w leczeniu zaburzeń sercowo-naczyniowych
CA2995094A1 (en) 2015-08-07 2017-02-16 Calcimedica, Inc. Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury
US10227315B2 (en) 2016-05-18 2019-03-12 Rutgers, The State University Of New Jersey Mitochondrial uncouplers for treatment of metabolic diseases and cancer
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
CA3057969A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
US11919902B2 (en) * 2017-12-22 2024-03-05 Hibercell, Inc. Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2020053834A1 (en) 2018-09-14 2020-03-19 Rhizen Pharmaceuticals Sa Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereof
EP3969449B1 (en) 2019-05-13 2025-02-12 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
CN110407740A (zh) * 2019-09-04 2019-11-05 上海毕得医药科技有限公司 一种3-溴-2-乙基吡啶的合成方法
JP2023528537A (ja) 2020-03-20 2023-07-04 カルシメディカ,インク. 急性肺傷害及び急性呼吸窮迫症候群を処置するための方法及び組成物
CA3198798A1 (en) 2020-11-13 2022-05-19 Kenneth Stauderman Improved synthesis of crac channel inhibitors
EP4516778A4 (en) 2022-04-25 2026-04-29 Nippon Shinyaku Co Ltd COMPOUND SERVING AS A DDR1 KINASE INHIBITOR AND MEDICINE

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI376370B (en) 2003-07-23 2012-11-11 Synta Pharmaceuticals Corp Compounds for inflammation and immune-related uses
KR20070057965A (ko) 2004-09-21 2007-06-07 신타 파마슈티칼스 코프. 염증 및 면역 관련 용도를 위한 화합물
KR20140018997A (ko) 2005-01-07 2014-02-13 신타 파마슈티칼스 코프. 염증 및 면역 관련 용도를 위한 화합물
EP1846388A4 (en) 2005-01-25 2011-12-07 Synta Pharmaceuticals Corp THIOPHEN COMPOUNDS FOR IGNITIONS AND THE IMMUNE SYSTEM APPLICATIONS
PL1848435T3 (pl) 2005-01-25 2016-08-31 Synta Pharmaceuticals Corp Związki przeciwko zapaleniom i zastosowania związane z odpornością
TW200806641A (en) 2006-01-25 2008-02-01 Synta Pharmaceuticals Corp Substituted aromatic compounds for inflammation and immune-related uses
TW200806290A (en) 2006-01-25 2008-02-01 Synta Pharmaceuticals Corp Substituted biaryl compounds for inflammation and immune-related uses
WO2007087429A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Phenyl and pyridyl compounds for inflammation and immune-related uses
US20070254926A1 (en) 2006-01-31 2007-11-01 Jun Jiang Pyridylphenyl compounds for inflammation and immune-related uses
ES2528797T3 (es) 2006-08-21 2015-02-12 Genentech, Inc. Compuestos de aza-benzotiofenilo y métodos de uso
CA2695148A1 (en) 2007-08-01 2009-02-05 Synta Pharmaceuticals Corp. Pyridine compounds for inflammation and immune-related uses
PT2195311E (pt) 2007-08-17 2011-05-25 Actelion Pharmaceuticals Ltd Derivados de piridina como moduladores do receptor s1p1/edg1
US8263641B2 (en) 2007-09-10 2012-09-11 Calcimedica, Inc. Compounds that modulate intracellular calcium
US8389567B2 (en) 2007-12-12 2013-03-05 Calcimedica, Inc. Compounds that modulate intracellular calcium
CA2725726A1 (en) 2008-05-23 2009-11-26 Glaxo Group Limited Tricyclic nitrogen containing compounds and their use as antibacterials
DE102008031299B4 (de) 2008-07-02 2014-10-30 Acandis Gmbh & Co. Kg Filter für ein Blutgefäß
TWI392673B (zh) 2008-08-27 2013-04-11 Calcimedica Inc 調控細胞內鈣離子濃度之化合物
US8524763B2 (en) 2008-09-22 2013-09-03 Calcimedica, Inc. Inhibitors of store operated calcium release
AU2009300318A1 (en) 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
TW201111380A (en) 2009-08-26 2011-04-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
EP2477982A4 (en) 2009-09-16 2013-04-03 Calcimedica Inc COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM
AU2011322068B2 (en) 2010-10-30 2015-11-05 Lupin Limited Oxazoline and isoxazoline derivatives as CRAC modulators
CA2834928C (en) 2011-05-03 2017-10-17 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
WO2013059677A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013059666A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium

Also Published As

Publication number Publication date
WO2013164769A1 (en) 2013-11-07
AU2013255437A1 (en) 2014-11-13
US20150111900A1 (en) 2015-04-23
EP2844655A1 (en) 2015-03-11
US9399638B2 (en) 2016-07-26
CA2871270A1 (en) 2013-11-07
ZA201407685B (en) 2015-11-25
US20160304506A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
IN2014MN02126A (2)
IN2014MN02127A (2)
UY32480A (es) Derivados de benzofuranilo
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
MX2013012896A (es) Compuestos novedosos como moduladores de proteina cinasas.
GEP20166438B (en) Imidazopyrrolidinone compounds
PH12015500551A1 (en) Tricyclic quinoline and quinoline derivatives
CR20110103A (es) Heteroarilos sustituidos
IN2014CN04907A (2)
MD20140109A2 (ro) Compuşi ai indolului şi indazolului care activează AMPK
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
MX367420B (es) Metodos y composiciones para inhibicion de proteinas que contienen bromodominio.
WO2012170931A3 (en) Compounds that modulate intracellular calcium
IN2012DN00943A (2)
MX2015012867A (es) Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
MX337711B (es) Compuestos que modulan el calcio intracelular.
PH12014501979A1 (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
TN2013000346A1 (en) Asymmetric ureas and medical uses thereof
PH12013500831A1 (en) Oxazoline and isoxazoline derivatives as crac modulators
WO2012170951A3 (en) Compounds that modulate intracellular calcium
PH12014501891A1 (en) Substituted chroman compounds as calcium sensing receptor modulators
AU2011322715A8 (en) Treatment of MeCP2-associated disorders
TW201613878A (en) Pyrazine GPR40 agonists for the treatment of type II diabetes
UY36081A (es) Compuestos inhibidores de metaloenzima como fungicidas.
HK1220699A1 (zh) 治疗神经退行性蛋白质病的化合物